Analysis of PD‐L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

(2018) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial

(2018) Alan Mackay et al.   CANCER CELL

Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response

(2018) Ashley S. Plant et al.   JOURNAL OF NEURO-ONCOLOGY

Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab

(2017) Francesco Passiglia et al.   INTERNATIONAL JOURNAL OF CANCER

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy

(2017) Song Xue et al.   Journal of Hematology & Oncology

Correlation of immune phenotype with IDH mutation in diffuse glioma

(2017) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme

(2017) Dieter Henrik Heiland et al.   Oncotarget

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

(2017) Anna C. Filley et al.   Oncotarget

The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis

(2017) Song Xue et al.   Scientific Reports

Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets

(2016) Tessa Johung et al.   Current Neuropharmacology

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

(2016) Sarah T. Garber et al.   NEURO-ONCOLOGY

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas

(2016) Jing Zeng et al.   Oncotarget

Brainstem Glioma in Adults

(2016) Jethro Hu et al.   Frontiers in Oncology

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas

(2014) Denise Bechet et al.   ACTA NEUROPATHOLOGICA

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

IT-11 * A PHASE I/ II CLINICAL TRIAL OF CT-011 (PIDILIZUMAB) IN DIFFUSE INTRINSIC PONTINE GLIOMA AND RELAPSED HIGH GRADE GLIOMA: A PRELIMINARY REPORT

(2014) I. Fried et al.   NEURO-ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients

(2014) APARAJITA BARAL et al.   Oncology Letters

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular analysis of diffuse intrinsic brainstem gliomas in adults

(2013) German Reyes-Botero et al.   JOURNAL OF NEURO-ONCOLOGY

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

(2013) Justyna Kmiecik et al.   JOURNAL OF NEUROIMMUNOLOGY

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

(2012) Dong-Anh Khuong-Quang et al.   ACTA NEUROPATHOLOGICA

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adult Brainstem Gliomas

(2012) G. Reyes-Botero et al.   ONCOLOGIST

Tumour-infiltrating T-cell subpopulations in glioblastomas

(2011) Young-Hee Kim et al.   BRITISH JOURNAL OF NEUROSURGERY

IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature

(2011) Prerana Jha et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Molecular profile of oligodendrogliomas in young patients

(2011) V. Suri et al.   NEURO-ONCOLOGY

B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells

(2009) Yu Yao et al.   NEURO-ONCOLOGY